Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the colon or rectum * Stage IV * Existence of two-dimensional measurable disease. The measurable disease should not have been irradiated. * Absence or irradiated and stable central nervous system metastatic disease. * Life expectancy of more than 3 months. * Age ≥ 70 years. * Performance status (WHO) ≤ 2. * Adequate bone marrow function (Absolute neutrophil count \>1000/mm3, Platelet count \>100000/mm3, Hemoglobin \>9gr/mm3). * Adequate liver (Bilirubin \<1.5 times upper limit of normal and SGOT/SGPT \<2 times upper limit of normal). * Creatinine clearance (Cockcroft-Gault formula) \>30ml/min. * No other invasive malignancy within the past 5 years except nonmelanoma skin cancer. * Presence of a reliable care giver. * Informed consent. Exclusion Criteria: * Prior chemotherapy for metastatic disease. * History of thromboembolic disease or myocardial infraction within the last 6 months. * Peripheral neuropathy ≥ grade 2. * Bowel obstruction or chronic diarrhea. * Psychiatric illness or social situation that would preclude study compliance. * Other concurrent uncontrolled illness. * Other concurrent investigational agents.